Literature DB >> 22754942

Herbal tonic does not inhibit estrogen receptor negative mammary tumor development in a transgenic mouse model.

L Michelle Bennett1, Jennifer L Montgomery, N Keith Collins, Seth M Steinberg, Kristen S Kulp.   

Abstract

Women who are diagnosed with breast cancer often self-administer complementary and alternative medicines to augment their conventional treatments, improve health, or prevent recurrence. Flor-Essence® herbal tonic is a complex mixture of eight herbal extracts used by cancer patients because of anecdotal evidence that it can treat or prevent disease. In this study four experimental groups of female MMTV-Neu mice were left untreated or treated with 3% Flor-Essence® in utero, from birth until 5 weeks of age, or throughout their lifetime. Palpable mammary tumor incidence and body weight was determined weekly for each group. The mice were sacrificed at 28 weeks of age and mammary tumors were enumerated to determine average tumor incidence and multiplicity for each group. Female mice exposed to Flor-Essence® herbal tonic in utero weighed significantly more than the control group (p < 0.001). The average tumor incidence and tumor multiplicity in the experimental mice treated with Flor-Essence® herbal tonic did not differ from the control animals. Flor-Essence® does not inhibit mammary tumor incidence or mammary tumor multiplicity in MMTV-Neu transgenic mice. Flor-Essence® exposure in utero causes increased body weight in experimental animals. This conclusion challenges widely available anecdotal information as well as the hopes of the consumer that this product will inhibit or suppress tumor development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22754942      PMCID: PMC3518418          DOI: 10.2202/1553-3840.1157

Source DB:  PubMed          Journal:  J Complement Integr Med        ISSN: 1553-3840


  30 in total

Review 1.  Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-04-07       Impact factor: 8.262

2.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

3.  Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats.

Authors:  W B Murrill; N M Brown; J X Zhang; P A Manzolillo; S Barnes; C A Lamartiniere
Journal:  Carcinogenesis       Date:  1996-07       Impact factor: 4.944

Review 4.  ERBB2 oncogene in human breast cancer and its clinical significance.

Authors:  F Révillion; J Bonneterre; J P Peyrat
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

5.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

Authors:  C T Guy; M A Webster; M Schaller; T J Parsons; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

6.  Effects of maternal xenoestrogen exposure on development of the reproductive tract and mammary gland in female CD-1 mouse offspring.

Authors:  Yasuyoshi Nikaido; Katsuhiko Yoshizawa; Naoyuki Danbara; Miki Tsujita-Kyutoku; Takashi Yuri; Norihisa Uehara; Airo Tsubura
Journal:  Reprod Toxicol       Date:  2004 Aug-Sep       Impact factor: 3.143

7.  Neonatal genistein chemoprevents mammary cancer.

Authors:  C A Lamartiniere; J Moore; M Holland; S Barnes
Journal:  Proc Soc Exp Biol Med       Date:  1995-01

Review 8.  Impact of environmental exposures on the mutagenicity/carcinogenicity of heterocyclic amines.

Authors:  James S Felton; Mark G Knize; L Michelle Bennett; Michael A Malfatti; Michael E Colvin; Kristen S Kulp
Journal:  Toxicology       Date:  2004-05-20       Impact factor: 4.221

Review 9.  The biology of erbB-2/neu/HER-2 and its role in cancer.

Authors:  N E Hynes; D F Stern
Journal:  Biochim Biophys Acta       Date:  1994-12-30

10.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.